{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for tedizolid root_relationships_relatedSubstance_refPname in Related Substance Name (approximate match)
Status:
US Approved Rx
(2015)
Source:
BLA125513
(2015)
Source URL:
First approved in 2015
Source:
BLA125513
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03319628: Phase 1/Phase 2 Interventional Active, not recruiting Platinum Resistant Ovarian Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:LIFASTUZUMAB [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01995188: Phase 1 Interventional Completed Non-Squamous Non-Small Cell Lung Cancer
(2013)
Source URL:
Class:
PROTEIN